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Inflammatory injury in the lung or dermis occurring after systemic activation of complement or after local deposition of immune complexes is related
to local activation of tissue macrophages and/or recruitment of blood neutrophils. While requirements for cytokines (IL-1, TNFa, MCP-1) vary with
the model of injury, requirements for adhesion molecules (32 integrins, selectins, ICAM-1) differ. In most cases the immediate events related to tis-
sue injury can be linked to toxic products from oxygen and L-arginine. Whether there is a single toxic product or a variety of toxic products remains
to be determined. These data emphasize similarities and differences in the mechanisms of inflammatory injury, as a function of the inciting inflam-
matory agent and the organ system involved. - Environ Health Perspect 102(Suppl 10):13-16 (1994)
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Introduction
Lung models of acute injury have been
instructive about the complicated cascade
of events leading to injury. In the models
to be described, injury ensues as a result of
recruitment and activation ofinflammatory
cells. In some cases blood leukocytes repre-
sent the exclusive source oftoxic products.
In other situations the toxic products are
derived from a combination of residential
phagocytic cells and recruited neutrophils.
In yet another situation it appears that
injury results exclusively from activation of
residential phagocytic cells. The three
models of acute lung injury (all in rats) are
systemic activation of complement by
cobra venom factor (CVF), intrapul-
monary deposition of IgG immune com-
plexes, and intrapulmonary deposition of
IgA complexes. In all cases it appears that
tissue injury is a result of oxidants gener-
ated from activated leukocytes and harmful
effects ofleukocyte-released proteases.
LungInjuryProducedbySystemic
Activation ofComplement
Intravascular (intravenous) infusion of the
purified cobra venom factor (CVF) into
rats causes massive, systemic (intravascular)
activation of the alternative pathway of
complement (1). Activation involving the
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third (C3) but not the fifth (C5) compo-
nent ofcomplement is insufficient to cause
injury (2). After infusion ofCVF and acti-
vation ofcomplement, intravascular activa-
tion of complement occurs, resulting in
stimulation of blood neutrophils. The fea-
tures ofCVC-induced lung injury are
. very rapid, early end point (30 min);
* complement and neutrophil-dependent;
. sensitive to catalase and deferroxamine;
* independent ofrequirements for TNFa
and IL-1;
* dependent on CD1la/CD18 and
CD lIb/CD18 and ICAM-1;
. dependent on P-selectin and L-selectin
but not E-selectin;
* damage occurring at endothelial interface
with neutrophils.
The presumed sequence of pathophysio-
logic events is as follows: As neutrophils
become activated, presumably by interac-
tion of C5a with cell surface receptors on
neutrophils, the cells undergo rapid homo-
typic aggregation, resulting in appearance
of intravascular cellular aggregates.
Simultaneously, contact with C5a leads to
rapid upregulation of CD1Ib/ CD18, the
heterodimeric 32 integrin complex that is
also known as Mac-I (MO-1). Increased
surface expression of CDl lb/ CD18 on
the neutrophil sets the stage for eventual
adhesive interaction with constitutively
expressed endothelial ICAM-1, the
counter-receptor' for CD11b/CD18, as
well as for CDI 1a/CD18 (LFA-1). The
latter molecule is not upregulated during
neutrophil activation. It appears that C5a
as well as C3a cause release of histamine
from rat mast cells and basophils.
Histamine has the ability to react with
receptors on endothelial cells, resulting in
rapid translocation of P-selectin from
Weible/Palade bodies to the surface of the
endothelial cell (3). P-selectin is a tran-
siently expressed glycoprotein of 140 kD
whose counter-receptor is some type of
glycoconjugate containing the oligosaccha-
ride, sialyl Lewisx. It seems likely that neu-
trophil adhesive interactions with P-selectin
expressed on endothelial cell surfaces, fol-
lowed by endothelial ICAM-1 engagement
with neutrophil LFA-1 and Mac-1, result
in a firm adhesive interaction between the
activated neutrophils and the adjacent vas-
cular endothelial cells.
Lung vascular injury in this model
occurs very rapidly, peaking within 30 min.
It would not be expected that this would
allow sufficient time for transcriptional and
translational upregulation of the cytokines
tumor necrosis factor alpha (TNFa) or
interleukin-I (IL-1); and, indeed, blocking
ofeither cytokine fails to cause any reduc-
tion in injury (4). Damage of vascular
endothelial cells is ascribable to toxic prod-
ucts generated from neutrophils that are in
direct contact with endothelial cells (1).
These products are derived from oxygen
that is metabolized during the respiratory
burst occurring in activated neutrophils.
This is characterized by an abrupt increase
in oxygen consumption and the formation
of superoxide anion (O-) and H20
Interception ofeither O2 (with superoxide
dismutase [SOD]) or H202 (with catalase)
will produce a substantial reduction in
lung injury, as shown in Table 1. The pro-
tective effects ofneutrophil or complement
depletion procedures in this model of
injury underscore the role of complement
and neutrophil activation products in
events leading to lung vascular injury.
Pretreatment of animals with the iron
chelator deferroxamine is also highly pro-
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Table 1. Protective interventions in CVF-induced lung
injury.
Intervention Reduction in lung injury, %
Neutrophil depletion 72
Complement depletion 65
Catalase 66
SOD 53
Deferroxamine 74
Fe-deferroxamine 0
Anti-E-selectina < 5
Anti-L-selectin 50
Anti-P-selectin 47
aAs determined by use of E-selectin-lg. Data from Till
et al. (1), Mulligan et al. (4), and Ward et al. (5).
tective, while use of the iron-saturated
form of this component is without effect.
While the precise interpretation of these
findings is unclear, the pattern is consistent
with the role of iron catalyzed conversion
of H202 to the hydroxyl radical ('OH),
that may be the oxygen product involved
in endothelial cell damage and necrosis (5).
Finally, evaluation of the role of all
known selectins in events leading to injury
in the CVF model reveals requirements for
L- and P-, but not E-selectins (6-8). This
"mapping" is achieved either by the use of
blocking antibodies or by the use of
selectin-Ig chimeric proteins that, because
of the presence of part of the Fc region of
IgG, conveys to the molecules a relatively
long half-life in the circulation (9). Once
again, the failure to identify a role of E-
selectin in this model is not surprising since
E-selectin is not constitutively expressed but
must be upregulated on the endothelial cell
surface following contact ofendothelial cells
with TNFa, IL-1, or bacterial lipopolysac-
charide (LPS). The ligand on the endothe-
lial cell for L-selectin in the neutrophil
remains to be identified. The requirement
in the CVF model of acute lung injury for
selectins has been further underscored by
the finding that intravascular infusion of
soluble sialyl Lewisx will protect against
injury (by greatly reducing changes in vas-
cular permeability and hemorrhage) in a
manner that reduces neutrophil accumula-
tion within the lungvasculature (10).
IgG Immune Complex-inducedAcute
LungInjury
Intrapulmonary deposition ofIgG immune
complexes in rats is achieved by the airway
instillation ofrabbit polyclonal antibody to
bovine serum albumin (BSA) and the intra-
venous infusion of BSA. Immune complex
deposition develops along alveolar walls.
The features of IgG immune complex-
induced lung injury are
* injury peaks at 4 hr;
* complement and neutrophil-dependent;
* requires toxic oxygen products ofneu-
trophils and pulmonary macrophages
(TNFoc, IL-1);
. sensitive to catalase and deferroxamine;
* requires L-arginine;
* dependent on CD11a/CD18 but not
CD11b/CD18; requires ICAM -1;
* requires E-selectin and L-selectin but
not P-selectin;
* extensive transmigration of neutrophils
into alveolar compartment.
The outcome, as measured 4 hr later, is
acute interstitial and intraalveolar edema
and hemorrhage, attendant with large accu-
mulations of neutrophils in the intraalveo-
lar compartment (11). The neutrophil
influx can be quantitated either by extrac-
tion ofmyeloperoxidase (MPO) from lung
tissue or by bronchoalveolar lavage (BAL)
and assessment of neutrophil numbers in
the BAL fluids.
Injury in this model requires availability
of both complement and neutrophils.
Depletion ofthe former interferes with neu-
trophil influx into the alveolar compartment
(11). Lack of availability of either comple-
ment or neutrophils causes a profound
reduction (62-77%) (Table 2) in tissue
injury. Toxic products of oxygen are also
involved in events leading to injury. This
has been determined by the protective
effects ofcatalase (which destroys H202) or
SOD, which has limited protective effects
(21%) in this model of lung injury (12).
Pretreatment ofanimals with the iron chela-
tor deferroxamine leads to a 53% reduction
in lung injury whereas the iron-saturated
form of this chelator is without effect (13).
These findings suggest the possibility of
iron-dependent reduction of H202 that
would result in production of 'OH,
although this is a presumptive conclusion.
There is also evidence that lung injury
Table 2. Protective interventions in IgG immune com-
plex-induced lung injury.a
Intervention Reduction in injury, %
Neutrophil depletion 77
Complement depletion 62
Catalase 75
SOD 21
Deferroxamine 53
Fe-deferroxamine < 5
L-NMA 55
Anti-E-selectin 95
Anti-L-selectin 33
Anti-P-selectin 0
aData from Mulligan et al. (7,8), Johnson and Ward
(11,12), Ward et al. (13), Beckman et al. (14), Mulligan
et al. (19), and Ward and Cochrane (20).
related to this model can be drastically
reduced in the presence of L-arginine ana-
logues, such as NG-monomethyl-L-arginine.
The pathway ofmetabolism ofL-arginine by
nitric oxide synthase (NOS) appears to be:
L-arginine -> 'NO (nitric oxide) and
citrulline
'NO +02 - ONOO' (peroxynitrite anion)
NO_
ONOO' + H+-> ONOOH-
-OH+NOI [1]
While 'NO is relatively nonreactive, peroxy-
nitrite anion (ONOO') is highly reactive, as
is 'OH (14) It seems that conversion of
NO to ONOO' is likely to occur especially
when 'NO production results from activa-
tion of phagocytic cells in which a some-
what acidic environment would be present,
as would be the case in an in vivo focus of
inflammation. The cogeneration of 01 (as
well as H202) would lead to the interaction
of 'NO with 01, and the subsequent bio-
chemical steps described above. What can-
not be accomplished at present is
identification ofthe precise toxic derivative
ofL-arginine, as well as the cellular target of
this factor. Although it has been shown in
murine macrophage-mediated killing of
tumor cells in vitro that 'NO or its deriva-
tive interacts with aconitase, thus interrupt-
ing the electron transport chain in the
Krebs cycle because of interaction with
iron-sulfur centers in the enzyme, it is not
clear ifthis can explain the effects observed
in the lung injury model (156).
In the IgG immune complex model,
the cytokines, substantial TNFa and IL-1,
appear in BAL fluids obtained 3 and 4 hr
after commencement ofIgG immune com-
plex deposition (16,17). These cytokines
are functionally active, since their quantita-
tion has been by employment ofbioassays.
Blocking of either cytokine leads to pro-
found reduction in the neutrophil influx
and reductions in the intensity of lung
injury (16,17). The linkage between neu-
trophil influx and cytokine presence may
be related to the ability ofIL-I and TNFoc
to cause vascular endothelial upregulation
of the adhesion molecules E-selectin and
ICAM-1. In view of the established
requirement for ICAM-1 in this model, the
requirements for P2 integrins are to be
expected and have been demonstrated
(18). What is unusual is the fact that neu-
trophil influx and accompanying lung
injury in this model requires CD1la/CD18
but not CD1lb/CD18. This is one of the
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few situations in which dual requirements
for both 32 integrins do not seem to per-
tain. The use ofblocking antibodies as well
as Ig-selectin chimeric preparations has
established that both E- and L-selectins are
required for neutrophil influx and injury in
this model (8,19). Blocking of these
selectins reduces injury (and neutrophil
accumulation) by 95 and 33%, respec-
tively. Blocking of P-selectin is without
effect, even though the same intervention
is highly protective in the CVF model of
acute lung injury. The ultimate injury
occurring after intrapulmonary deposition
of IgG immune complex involves toxic
products from both oxygen as well as L-
arginine, as described above.
IgG Immune Complex-induced
DermalVascular Injury
Studies companion to those described
above in the IgG immune complex model
of acute lung injury have been completed.
Anti-BSA is injected intradermally, while
BSA is infused intravenously. IgG immune
complex deposition occurs primarily in
venular walls in the dermis, resulting in
complement activation and the influx of
neutrophils (19,20). Depletion of either
complement or neutrophils reduces injury
by 65 to 68% (Table 3). One especially sur-
prising finding has been that, while being
highly protective against lung injury follow-
ing deposition of the same IgG immune
complexes, in the dermis the presence of
catalase is without any protective effects,
even though SOD is highly protective
(21,22). This could suggest that dermal
vascular endothelial cells are resistant to
toxic oxygen products. Alternatively, the
fact that SOD is highly protective in this
model (reducing injury by 78%), and the
finding that L-NMA is also significantly
protective (23), could suggest that the chief
agent of injury is related to interactions of
-NO with °2 to produce ONOO-, and
ultimately, perhaps OH (see above). The
protective effects ofdeferroxamine might be
related to a recent observation that this
Table 3. Protective interventions in IgG immune
complex-induced dermal vascular injury.a
Intervention Reduction in lung injury, %
Neutrophil depletion 68
Complement depletion 65
Catalase 0
SOD 78
Deferroxamine 65
L-NMA 58
aData from Johnson and Ward (21), McCormick et al.
(22), Mulligan et al. (23), and Mulligan and Ward (24).
compound, being a potent iron chelator,
can also react with ONOO* to bring about
its chemical inactivation (14). Recent stud-
ies have also demonstrated that IgG
immune complex-induced dermal vasculitis
requires IL-I but not TNFa (24). This has
been determined by the use of blocking
antibodies, or by the use of TNFa recep-
tor-I or IL-1 receptor antagonist. Immuno-
histochemical studies reveal the appearance
of IL-1, but not TNFa, in interstitial cells
within the dermis following immune com-
plex deposition (24). Why TNFa is not
elaborated in the dermis under these condi-
tions whereas in the lung there is abundant
elaboration of both TNFa and IL-1 is
unclear. Studies employing the intradermal
coadministration of either TNFa or IL-1
with the anti-BSA have revealed that the
recruitment of neutrophils and the expres-
sion of dermal vascular injury are both
enhanced under such conditions (24). This
demonstrates that the dermal vasculature is
indeed reactive to both cytokines. Whatever
the details, it is clear that the pathophysiol-
ogy of dermal vascular injury is different
when compared to similar injury occurring
in the lung.
IgAImmune Complex-induced
LungInjury
Features of IgA immune complex-induced
lunginjury are
* injury peaks at 4 hr;
* complement-dependentbutneutrophil-
independent;
* requiresproductsofactivatedpulmonary
macrophages;
* sensitive to catalase, SOD and deferrox-
amine;
* requires L-arginine;
* dependent on MCP-I but independent
ofTNFa and IL-1;
* dependent on CD1I a/CD18;
CDI lb/CD18 and ICAM-1
* independent ofrequirements for L-, E-
and P-selectins;
* injury appears to be dependent on acti-
vated residential pulmonarymacrophages.
Injury in this model is induced by the
intratracheal instillation of murine mono-
clonal IgGI anti-dinitrophenol (anti-DNP)
followed by the intravenous infusion of
DNP-BSA. Neutrophil depletion does not
protect against injury, which is character-
ized byextensive injury ofalveolar epithelial
lining cells (25,26) (Table 4). Very few
neutrophils appear in BAL fluids or in tis-
sue sections of lung. The injury seems to
involve the activation of pulmonary
macrophages by IgA immune complexes
and complement activation products. IgA
immune complexes alone seem insufficient
to cause macrophage-mediated injury. The
complement requirement probably relates
to the need for opsonization of complexes
and the generation of complement activa-
tion products, the combination with com-
plexes leading to macrophage activation.
Pulmonary injury in this model is highly
susceptible to the protective effects ofcata-
lase, SOD, and deferroxamine (Table 4). As
expected, iron-saturated deferroxamine is
without protective effects. There is com-
pelling evidence in this model that toxic
products from L-arginine play an important
role, since the use of L-NMA leads to a
high degree of protection (67%) (27).
With respect to cytokine requirements, very
little TNFa and IL-I appear in the BAL
fluids ofthese animals. Not surprising, anti-
TNFa or anti-IL-1 do not reduce the inten-
sity of injury following (28). In contrast,
blocking of monocyte chemotactic protein
(MCP-1) by antibody reduces IgG immune
complex-induced lung injury significantly
(approximately 80%) whereas this interven-
tion in the IgG immune complex model of
acute lung injury is without effect (29).
This sharply defines the requirement for
cytokines in these two models of immune
complex-induced lung injury. 32 integrin
requirements in this model of injury
demonstrate the involvement of both
CDIIa/CD18 and CDIIb/CD18, and, as
anticipated, the requirement for the
"counter receptor" for these P2 integrins,
ICAM-1 (27). Since there appears to be lit-
tle ifany need for the recruitment ofblood
leukocytes into the lung in this model of
injury, it is not surprising that the process
appears to be independent ofa requirement
for any of the three selectins (8). Taken
together, these studies suggest that injury in
this model is due to activation ofresidential
intrapulmonary macrophages. Their activa-
tion probably requires involvement of
CD11a/CD18 as well as CD11b/CD18,
Table 4. Protective interventions in IgA immune
complex-induced lung injury.3
Intervention Reduction in injury, %
Neutrophil depletion 76
Complement depletion < 5
Catalase 95
SOD 100
Deferroxamine 77
Fe-deferroxamine 0
L-NMA 67
Anti-E-selectin 11
Anti-L-selectin 6
Anti-P-selectin 5
"Data from Johnson et al. (25), Warren et al. (26),
Mulligan et al. (27,28), and Jones et al. (29).
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and lung injury is attributable to generation
oftoxic products from L-arginine as well as
from oxygen. The demonstrated require-
ment in this model for ICAM-1 may be
related to the anchoring of alveolar
macrophages, via their 12 integrins, to
ICAM-1 which is constitutively expressed
on Type I alveolar epithelial cells.
Conclusion
Inflammatory injury as described in the
various animal models is more complicated
than first imagined. Differences have been
found when comparing IgG immune com-
plex-induced dermal vascular and lung
injury and in the same organ (lung) when
comparing two different stimuli (IgG ver-
sus IgA immune complexes). In part these
differences can be related to the types of
cytokines appearing in tissues after initia-
tion ofthe inflammation ofthe inflamma-
tory response. One of the more important
in vivo functions of cytokines such as
TNFa and IL-1 appears to be upregulation
of vascular adhesion molecules. Another
obvious pattern of differences is found in
the role of the various adhesion molecules
required for the full development ofinjury
in these models. Why in the case of IgG
immune complex-induced lung injury
CDlla but not CDllb is important is
unclear. The one finding that appears to
link all of these models, whether or not
blood leukocyte recruitment is required, is
the role ofoxidants derived from oxygen as
well as L-arginine. These toxic products
appear to derive from phagocytic cells,
either residential or recruited from the
blood. A major problem at present is to
define the patterns of differences (with
respect to mediators required for injury)
within the same organ and between organs,
and to determine not only the chemical
nature of the toxic oxidants but their tar-
gets as well. This information will assist in
the development of therapeutic strategies
designed to protect against harmful effects
ofthe inflammatory response.
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